CORT Share Price Performance
US$35.69
-19.80 (-35.68%)
53.3% undervalued intrinsic discount
US$76.40
Fair Value
Price US$35.69
AnalystConsensusTarget US$76.40
Giuca US$63.53
AnalystLowTarget US$95.00
Fair ValueUS$76.40
Share Pricen/a
Corcept Therapeutics Incorporated Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 129 Fair Values set on narratives written by author
CORT Community Narratives
AN
Fair Value US$76.4 53.3% undervalued intrinsic discount
Patient Screening And Regulatory Approvals Will Unlock Global Markets
0users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
GI
Fair Value US$63.53 43.8% undervalued intrinsic discount
Corcept and its fair value according my DCF valuation
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$95 62.4% undervalued intrinsic discount
Cortisol Modulation Risks May Overshadow Oncology Ambitions Yet Long-Term Prospects Remain Appealing
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Corcept and its fair value according my DCF valuation
Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato.Read more
79
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Patient Screening And Regulatory Approvals Will Unlock Global Markets
Key Takeaways Expanding disease awareness, anticipated drug approvals, and enhanced commercial operations are set to propel revenue growth and decrease reliance on a single product. Favorable demographic trends and proven regulatory execution support ongoing market and earnings expansion for the company.Read more
901
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
AN
US$76.4
53.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
28.35% p.a.
Profit Margin
36.02%
Future PE
16.9x
Price in 2029
US$92.93
Upcoming Hypercortisolism And Oncology Approvals Will Transform This Cortisol Modulation Leader
Catalysts About Corcept Therapeutics Corcept Therapeutics develops selective cortisol modulators to treat serious endocrine, metabolic and oncologic diseases. What are the underlying business or industry changes driving this perspective?Read more
45
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$121
70.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
37.51% p.a.
Profit Margin
36.75%
Future PE
21.79x
Price in 2029
US$148.05
Cortisol Modulation Risks May Overshadow Oncology Ambitions Yet Long-Term Prospects Remain Appealing
Catalysts About Corcept Therapeutics Corcept Therapeutics develops proprietary selective cortisol modulators to treat endocrine, oncologic, neurologic and metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
88
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$95
62.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
33.35% p.a.
Profit Margin
31.78%
Future PE
21.69x
Price in 2028
US$116.24
Trending Discussion
Recently Updated Narratives
GI
Corcept and its fair value according my DCF valuation
Fair Value: US$63.53 43.8% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Fair Value: US$76.4 53.3% undervalued intrinsic discount
56 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Upcoming Hypercortisolism And Oncology Approvals Will Transform This Cortisol Modulation Leader
Fair Value: US$121 70.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Corcept Therapeutics Incorporated Key Details
About CORT
- Founded
- 1998
- Employees
- 730
- CEO
- WebsiteView website
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
